GMED EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
GMED's ev/ebitda is lower than 95% of the last 10 years.
EV/EBITDA History
GMED EV/EBITDA by year
Yearly range of GMED’s ev/ebitda from 2016 to 2026. Over the full period it ranged from 9.4 to 39.2, averaging 21.3.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 11.3 | 13.3 | 15.7 | 11.4 |
| 2025 | 10.3 | 16.4 | 27.1 | 14.2 |
| 2024 | 19.4 | 23.8 | 27.7 | 23.9 |
| 2023 | 14.7 | 18.4 | 26.3 | 19.5 |
| 2022 | 20.5 | 25.1 | 31.9 | 27.5 |
| 2021 | 20.6 | 30.0 | 37.5 | 27.7 |
| 2020 | 15.2 | 27.4 | 39.2 | 35.7 |
| 2019 | 17.2 | 22.0 | 27.0 | 26.0 |
| 2018 | 18.6 | 23.4 | 27.2 | 19.6 |
| 2017 | 12.1 | 14.6 | 19.5 | 19.2 |
| 2016 | 9.4 | 10.3 | 11.4 | 11.4 |
Get notified when GMED EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is GMED EV/EBITDA High or Low Right Now?
Globus Medical, Inc.'s EV/EBITDA is currently 11.4, which is near historic low relative to its 10-year historical range. The 10-year median EV/EBITDA for GMED is approximately 21.7. See all GMED valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.